Heron Therapeutics
HRTX
193 hedge funds and large institutions have $1.1B invested in Heron Therapeutics in 2020 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 81 increasing their positions, 49 reducing their positions, and 42 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 49
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 42
3% less funds holding
Funds holding: 199 → 193 (-6)
7.31% less ownership
Funds ownership: 109.99% → 102.69% (-7.3%)
39% less call options, than puts
Call options by funds: $5.87M | Put options by funds: $9.66M
53% less capital invested
Capital invested by funds: $2.33B → $1.1B (-$1.23B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$46.7M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$26.3M |
| 3 |
Renaissance Technologies
New York
|
+$16.4M |
| 4 |
JP Morgan Chase
New York
|
+$10.4M |
| 5 |
O
OrbiMed
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.4M |
| 2 |
BM
Bridger Management
New York
|
-$40.5M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$39.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$38.7M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$32.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAS
226
Winch Advisory Services
Appleton,
Wisconsin
| – | -$22K | -939 | Closed |
|
|
LC
227
Lindbrook Capital
Calabasas,
California
| – | -$12K | -500 | Closed |
|
|
EWA
228
Evolution Wealth Advisors
Aventura,
Florida
| – | -$9K | -381 | Closed |
|
|
PCM
229
Prelude Capital Management
New York
| – | -$5.53K | -294 | Closed |
|
|
WT
230
Whittier Trust
South Pasadena,
California
| – | -$2K | -75 | Closed |
|
231
First Manhattan
New York
| – | +$752 | +40 | New |
|
|
JCM
232
Jacobi Capital Management
Pittston,
Pennsylvania
| – | +$771 | +41 | New |
|
HRTX Hedge Fund Activity: Q1 2020 in Review
193 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2020, worth a combined $1.1B — down 53% from $2.33B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of HRTX and 40 opened new positions — a net loss of 2 holders — while 49 trimmed existing stakes and 81 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $46.7M. The largest seller was Fidelity Investments, cutting an estimated $76.4M.
- 193 institutional investors held Heron Therapeutics (HRTX) as of Q1 2020, down from 199 in Q4 2019.
- Funds reported $1.1B of Heron Therapeutics stock for Q1 2020, down 53% quarter-over-quarter.
- 40 funds opened new Heron Therapeutics positions in Q1 2020 and 42 closed out, a net change of -2 holders.
- The largest Heron Therapeutics buyer in Q1 2020 was PFM Health Sciences, an estimated $46.7M added.
- The largest Heron Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $76.4M sold.
Based on aggregated 13F filings for Q1 2020.